Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph V Newman

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|December 19, 2018
Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy SubjectsJoseph V Newman, Jian Zhou, Sergey Izmailyan, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2018
Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of EravacyclineJoseph V Newman, Jian Zhou, Sergey Izmailyan, et al.
International Journal of Antimicrobial Agents|January 13, 2018
Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysisAbrar K Thabit, Marguerite L Monogue, Joseph V Newman, et al.
Journal of Proteome Research|December 25, 2003
Genome-wide profile of oxidoreductases in viruses, prokaryotes, and eukaryotesRichard Kho, Joseph V Newman, Richard M Jack, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2015
Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacyBoudewijn L M de Jonge, Amy Kutschke, Joseph V Newman, et al.
Plos One|March 6, 2014
Secreted Gaussia princeps luciferase as a reporter of Escherichia coli replication in a mouse tissue cage model of infectionMingyu Liu, Christina Blinn, Sarah M McLeod, et al.
Proteins|February 11, 2003
A path from primary protein sequence to ligand recognitionRichard Kho, Brian L Baker, Joseph V Newman, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2014
NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacyThomas J Dougherty, Asha Nayar, Joseph V Newman, et al.
Bioorganic & Medicinal Chemistry Letters|December 14, 2011
Discovery of bacterial NAD⁺-dependent DNA ligase inhibitors: improvements in clearance of adenosine seriesSuzanne S Stokes, Madhusudhan Gowravaram, Hoan Huynh, et al.
Nature Communications|September 16, 2024
Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma modelsWilliam Senapedis, Kayleigh M Gallagher, Elmer Figueroa, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|December 19, 2018
Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy SubjectsJoseph V Newman, Jian Zhou, Sergey Izmailyan, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2018
Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of EravacyclineJoseph V Newman, Jian Zhou, Sergey Izmailyan, et al.
International Journal of Antimicrobial Agents|January 13, 2018
Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysisAbrar K Thabit, Marguerite L Monogue, Joseph V Newman, et al.
Journal of Proteome Research|December 25, 2003
Genome-wide profile of oxidoreductases in viruses, prokaryotes, and eukaryotesRichard Kho, Joseph V Newman, Richard M Jack, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2015
Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacyBoudewijn L M de Jonge, Amy Kutschke, Joseph V Newman, et al.
Plos One|March 6, 2014
Secreted Gaussia princeps luciferase as a reporter of Escherichia coli replication in a mouse tissue cage model of infectionMingyu Liu, Christina Blinn, Sarah M McLeod, et al.
Proteins|February 11, 2003
A path from primary protein sequence to ligand recognitionRichard Kho, Brian L Baker, Joseph V Newman, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2014
NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacyThomas J Dougherty, Asha Nayar, Joseph V Newman, et al.
Bioorganic & Medicinal Chemistry Letters|December 14, 2011
Discovery of bacterial NAD⁺-dependent DNA ligase inhibitors: improvements in clearance of adenosine seriesSuzanne S Stokes, Madhusudhan Gowravaram, Hoan Huynh, et al.
Nature Communications|September 16, 2024
Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma modelsWilliam Senapedis, Kayleigh M Gallagher, Elmer Figueroa, et al.
Pageof 3